Harpoon Therapeutics: Pursuant To The Merger Agreement, At The Effective Time Of The Merger (the Effective Time ), (a) Each Share Of Harpoon Common Stock (other Than (i) Shares Held In The Treasury Of Harpoon Or Owned By Merck Or Merger Sub Or Any Direct Or Indirect Wholly Owned Subsidiary Of Merck Or Harpoon Immediately Prior To The Effective Time And (ii) Shares Held By Stockholders Who Have Perfected Their Statutory Rights Of Appraisal Under Section 262 Of The Delaware General Corporation Law (clauses (i) And (ii) Together, The Excluded Shares )) Was Cancelled And Converted Automatically Into The Right To Receive $23.00 In Cash, Without Interest, With Respect To Such Shares Of Harpoon Common Stock (the Merger Consideration ), Subject To Applicable Withholding Taxes, And (b) Each Share Of Series A Preferred Stock, Par Value $0.0001 Per Share, Of Harpoon (the Preferred Shares ) Issued And Outstanding Immediately Prior To The Effective Time (other Than Any Excluded Shares) Was Cancelled And The Holder Is Entitled To Receive $3,577.77 In Respect Of Each Preferred Share Determined In Accordance With The Terms Of The Preferred Shares, Subject To Applicable Withholding Taxes, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Change In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Harpoon Therapeutics Inc
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***